Steven Pieper - Jan 29, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 29, 2022
Transactions value $
-$454,284
Form type
4
Date filed
8/9/2024, 04:06 PM
Previous filing
Jan 5, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability -$7.3K -3.46K -0.21% $2.11* 1.62M Jan 29, 2022 Direct F1, F2
transaction XERS Common Stock Tax liability -$1.58K -750 -0.05% $2.11* 1.62M Jan 31, 2022 Direct F1, F3
transaction XERS Common Stock Tax liability -$14K -9.77K -0.6% $1.43* 1.61M Jul 28, 2022 Direct F1, F4
transaction XERS Common Stock Tax liability -$25.8K -23.1K -1.43% $1.12 1.59M Jan 3, 2023 Direct F1, F5
transaction XERS Common Stock Tax liability -$4.52K -3.59K -0.23% $1.26 1.59M Jan 29, 2023 Direct F1, F6
transaction XERS Common Stock Tax liability -$965 -778 -0.05% $1.24 1.59M Jan 31, 2023 Direct F1, F7
transaction XERS Common Stock Tax liability -$25.8K -10.2K -0.64% $2.53 1.58M Jul 28, 2023 Direct F1, F8
transaction XERS Common Stock Tax liability -$51.7K -23.1K -1.46% $2.24 1.55M Jan 3, 2024 Direct F1, F9
transaction XERS Common Stock Tax liability -$11.6K -4.38K -0.28% $2.66 1.55M Jan 29, 2024 Direct F1, F10
transaction XERS Common Stock Tax liability -$272K -111K -7.16% $2.46 1.44M Jan 31, 2024 Direct F1, F11
transaction XERS Common Stock Tax liability -$38.5K -14.8K -1.03% $2.61 1.42M Jul 28, 2024 Direct F1, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is being reported late due to administrative oversight.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January, 29, 2022.
F3 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2023.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F11 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
F12 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of July 28, 2024.

Remarks:

Chief Financial Officer